Cat. No.: HY-N0696

Sipeimine

(Synonyms: Imperialine)

4 Cited Publications

Customer Review

Based on 4 publication(s) in Google Scholar

Sipeimine (Imperialine) is an inhibitor targeting the PI3K/AKT/NF-κB pathway and NLRP3 inflammasome, which can competitively bind to PI3K and p65. Sipeimine inhibits PI3K/AKT phosphorylation, blocks NF-κB nuclear translocation and NLRP3 inflammasome activation. Sipeimine exerts anti-inflammatory activities, inhibits pyroptosis and ferroptosis, and protects the extracellular matrix. Sipeimine can reduce cartilage degradation and synovial inflammation in osteoarthritis and improve PM2.5-induced lung injury. Sipeimine is mainly used in the study of anti-inflammatory and degenerative diseases.

For research use only. We do not sell to patients.

Purity: 98.57%
CAS No.: 61825-98-7
Formula: C₂₇H₄₃NO₃
Molecular Weight:429.64

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Sipeimine Chemical Structure

CAS No.: 61825-98-7

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Publications (4)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

All PI3K Isoforms :

All NF-κB Isoforms :

All Akt Isoforms :

All NOD-like Receptor (NLR) Isoforms :

In Vitro

Sipeimine (100 μM, 200 μM; 24-48 h) significantly reduces cell viability in mouse chondrocytes^[1].
Sipeimine (10-50 μM; 24 h) dose-dependently inhibits lipopolysaccharide (LPS)-induced cytotoxicity in the LDH release assay^[1].
Sipeimine (25 μM, 50 μM; 24 h) inhibits the mRNA and protein expression of proinflammatory factors (COX-2, iNOS, IL-1β, IL-18) in 1 μg/mL LPS-induced mouse chondrocytes and reduces PGE2 and nitrite production^[1].
Sipeimine (25 μM, 50 μM; 4 h) increases the extracellular matrix components (collagen-II, aggrecan) and reduces the protein expression of degradative enzymes (MMP-13, ADAMTS-5) in mouse chondrocytes in WB experiments^[1].
Sipeimine (50 μM; 2-24 h) inhibits LPS-induced NF-κB pathway activation (reduced p-IκBα, p-p65 phosphorylation and p65 nuclear translocation) and NLRP3 inflammasome-mediated cell pyroptosis (reduced NLRP3, ASC, cleaved-caspase-1, cleaved-GSDMD protein expression) in mouse chondrocytes^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR^[1]

Cell Line:

Mouse chondrocytes
Concentration:

0, 25, 50 μM
Incubation Time:

24 h (after LPS stimulation)
Result:

Significantly reduced the mRNA levels of pro-inflammatory factors (IL-1β, IL-18, COX-2, iNOS) induced by LPS.

Western Blot Analysis^[1]

Cell Line:

Mouse chondrocytes
Concentration:

0, 25, 50 μM
Incubation Time:

24 h (after LPS stimulation)
Result:

Decreased the protein expressions of COX-2, iNOS, MMP-13, ADAMTS-5, NLRP3, ASC, cleaved-caspase-1, cleaved-GSDMD, p-IκBα, and p-p65, while increased the expressions of collagen-II, aggrecan, and total IκBα, AKT, PI3K.

In Vivo

Sipeimine (30 mg/kg; intra-articular injection; once daily; 14 days) can reduce cartilage degradation, subchondral bone remodeling, synovial inflammation and extracellular matrix (ECM) degradation in the DMM-induced osteoarthritis (OA) mouse model^[1].
Sipeimine (15, 30 mg/kg; intraperitoneal injection; once daily; 3 days) can reduce lung tissue damage, pulmonary edema, inflammatory response, inhibit ferroptosis-related indicators (4-HNE, MDA, tissue iron) and upregulate antioxidant factors (GSH, Nrf2, GPX4, HO-1) in the PM2.5-induced lung injury Sprague-Dawley rat model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 mice (8-10 weeks old), medial meniscus destabilization (DMM)-induced OA model^[1]
Dosage:

30 mg/kg (dissolved in saline with 0.1% DMSO).
Administration:

Intra-articular injection, once daily for 14 days, followed by an 8-week observation period.
Result:

Significantly reduced subchondral bone volume/tissue volume (BV/TV), trabecular thickness (Tb.Th), and trabecular number (Tb.N), and increased trabecular separation (Tb.Sp) compared to the DMM group.
Histological analysis using Safranin O-fast green and H&E staining showed decreased cartilage degeneration (lower OARSI scores) and synovitis.
Immunohistochemistry revealed reduced expressions of MMP-13, NLRP3, and p-PI3K, and increased collagen-II expression in cartilage tissues.

Animal Model:

Male Sprague-Dawley rats (8 weeks old, 110-150 g), PM2.5-induced lung injury model via intratracheal instillation of PM2.5 (7.5 mg/kg/day for 2 days)^[2]
Dosage:

15 mg/kg and 30 mg/kg (dissolved in saline with 0.1% DMSO).
Administration:

Intraperitoneal injection, once daily for 3 days before PM2.5 exposure.
Result:

Dose-dependently alleviated PM2.5-induced lung injury, as indicated by reduced histological scores (thickened alveolar walls, inflammatory cell infiltration, hemorrhage), lower lung wet/dry (W/D) ratio, and decreased levels of TNF-α and IL-1β in bronchoalveolar lavage fluid (BALF).
Reversed PM2.5-induced increases in tissue iron, 4-HNE, and MDA, and restored GSH levels.
Transmission electron microscopy showed attenuated mitochondrial morphological changes (reduced cristae loss and electron density) in type II alveolar epithelial cells.
Western blot revealed upregulated expressions of Nrf2, GPX4, HO-1, SLC7A11, and FTH1, and increased phosphorylation of PI3K and Akt.

Chemical Information

CAS No. 61825-98-7
Appearance Solid
Molecular Weight 429.64
Formula C₂₇H₄₃NO₃
Color White to off-white
SMILES

C[C@@]([C@@]1([H])C2=O)(CC[C@H](O)C1)[C@]3([H])[C@](C2)([H])[C@@](CC[C@]4([H])[C@@]5([H])CN(C[C@@H](C)CC6)[C@]6([H])[C@]4(O)C)([H])[C@@]5([H])C3
Synonyms

Imperialine
Structure Classification
- Alkaloids
- Piperidine Alkaloids
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (4)

All

Sort by:

Journal Impact Factor

Phytomedicine

Total alkaloids of Fritillaria unibracteata var. wabuensis bulbus ameliorate chronic asthma via the TRPV1/Ca2+/NFAT pathway. [Abstract]

2023 Sep:118:154946. PMID: 37421766
Molecules

hERG Channel Blockade and Antagonistic Interactions of Three Steroidal Alkaloids from Fritillaria Species. [Abstract]

2025 Sep 25;30(19):3882. PMID: 41097303
Molecules

Metabolite Profiling and Anti-Inflammatory Activities of Fritillaria cirrhosa D. Don Bulbs Derived from Tissue Culture. [Abstract]

2025 Jan 31;30(3):623. PMID: 39942727
Sci Rep

Sipeimine reduces ethanol-induced gastric ulcer in mice by suppressing Jak-Stat activation and restoring gut microbiota balance. [Abstract]

2025 Aug 6;15(1):28683. PMID: 40770008

Solvent & Solubility

In Vitro:

DMSO : 8.33 mg/mL (19.39 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3275 mL

11.6376 mL

23.2753 mL

5 mM

0.4655 mL

2.3275 mL

4.6551 mL

10 mM

0.2328 mL

1.1638 mL

2.3275 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 0.77 mg/mL (1.79 mM); Clear solution

This protocol yields a clear solution of ≥ 0.77 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (7.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 0.77 mg/mL (1.79 mM); Clear solution

This protocol yields a clear solution of ≥ 0.77 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (7.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 0.77 mg/mL (1.79 mM); Clear solution

This protocol yields a clear solution of ≥ 0.77 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (7.7 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Fang Y, et al. Sipeimine ameliorates osteoarthritis progression by suppression of NLRP3 inflammasome-mediated pyroptosis through inhibition of PI3K/AKT/NF-κB pathway: An in vitro and in vivo study. J Orthop Translat. 2024 May 9;46:1-17. [Content Brief]

[2]. Wang Y, et al. Sipeimine ameliorates PM2.5-induced lung injury by inhibiting ferroptosis via the PI3K/Akt/Nrf2 pathway: A network pharmacology approach. Ecotoxicol Environ Saf. 2022 Jul 1;239:113615. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3275 mL	11.6376 mL	23.2753 mL	58.1882 mL
	5 mM	0.4655 mL	2.3275 mL	4.6551 mL	11.6376 mL
	10 mM	0.2328 mL	1.1638 mL	2.3275 mL	5.8188 mL
	15 mM	0.1552 mL	0.7758 mL	1.5517 mL	3.8792 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Sipeimine

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Alkaloids Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cysteine Targeted Covalent Library

Autoimmune Disease Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Inflammasomes related Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Tibetan Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Pattern Recognition Receptors Library

Mongolian Medicine Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Sipeimine

All PI3K Isoforms

All NF-κB Isoforms

All Akt Isoforms

All NOD-like Receptor (NLR) Isoforms

Biological Activity

Chemical Information

Publications (4)